Although the mechanisms underlying increased expression of AML1 are currently unknown, monitoring the amounts of AML1, as well as the emergence of its mutants along with additional genetic changes, may provide a better understanding of the roles of altered AML1 in the disease progression of CML. This evidence concerns the gene RUNX1 and chronic myelogenous leukemia, BCR-ABL1 positive.